Noah Goodman Biography and Net Worth

Chief Business Officer of Kymera Therapeutics

Noah Goodman is the Chief Business Officer at Kymera Therapeutics. Before joining Kymera, Noah held senior leadership roles at Chroma Medicine and nChroma Bio, serving as President and Chief Business Officer through the merger with Nvelop Therapeutics. He also served as Executive Director and Head of Business Development at Cadent Therapeutics, which was subsequently acquired by Novartis, and Seres Therapeutics, where he was responsible for leading collaborations and licensing transactions across several therapeutic areas. Earlier in his career, Noah also worked in business development at Spark Therapeutics and served as a management consultant at Easton Associates, a boutique life sciences consultancy. He holds a B.S. in neuroscience from the University of Michigan and an M.B.A. from the Wharton School of the University of Pennsylvania.

What is Noah Goodman's net worth?: The estimated net worth of Noah Goodman is at least $4.32 million as of April 14th, 2026. Mr. Goodman owns 50,195 shares of Kymera Therapeutics stock worth more than $4,323,797 as of April 16th. This net worth approximation does not reflect any other investments that Mr. Goodman may own. Learn More about Noah Goodman's net worth.
How do I contact Noah Goodman?: The corporate mailing address for Mr. Goodman and other Kymera Therapeutics executives is 200 Arsenal Yards Blvd. Suite 230, Watertown MA, 02472. Kymera Therapeutics can also be reached via phone at 857-285-5300 and via email at [email protected]. Learn More on Noah Goodman's contact information.
Has Noah Goodman been buying or selling shares of Kymera Therapeutics?: During the last ninety days, Noah Goodman has sold $1,019,030.00 in shares of Kymera Therapeutics stock. Most recently, Noah Goodman sold 1,347 shares of the business's stock in a transaction on Tuesday, April 14th. The shares were sold at an average price of $90.00, for a transaction totalling $121,230.00. Following the completion of the sale, the insider now directly owns 50,195 shares of the company's stock, valued at $4,517,550. Learn More on Noah Goodman's trading history.
Who are Kymera Therapeutics' active insiders?: Kymera Therapeutics' insider roster includes Jeffrey Albers (Director), Bruce Booth (Director), Jeremy Chadwick (COO), Richard Chesworth (Insider), Ellen Chiniara (Chief Legal Officer and Corporate Secretary), Jared Gollob (Insider), Noah Goodman (Chief Business Officer), Bruce Jacobs (CFO), Nello Mainolfi (CEO), and Elena Ridloff (Director). Learn More on Kymera Therapeutics' active insiders.
Are insiders buying or selling shares of Kymera Therapeutics?: In the last twelve months, Kymera Therapeutics insiders bought shares 3 times. They purchased a total of 2,978,480 shares worth more than $215,297,266.00. In the last twelve months, insiders at the sold shares 39 times. They sold a total of 1,020,588 shares worth more than $80,707,029.90. The most recent insider tranaction occured on April, 15th when COO Jeremy G Chadwick sold 1,300 shares worth more than $117,000.00. Insiders at Kymera Therapeutics own 16.0% of the company. Learn More about insider trades at Kymera Therapeutics.
Information on this page was last updated on 4/15/2026.

Noah Goodman Insider Trading History at Kymera Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/14/2026	Sell	1,347	$90.00	$121,230.00	50,195
4/10/2026	Sell	2,000	$87.35	$174,700.00	51,542
4/9/2026	Sell	8,264	$87.50	$723,100.00	53,542

Noah Goodman Buying and Selling Activity at Kymera Therapeutics

Kymera Therapeutics Company Overview

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Today's Range

Now: $86.14

$84.64

$89.23

50 Day Range

MA: $83.89

$74.42

$95.03

2 Week Range

Now: $86.14

$24.72

$103.00

Volume

554,950 shs

Average Volume

612,108 shs

Market Capitalization

$7.03 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.28